Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Biosimilar Enbrel: Sandoz, FDA Panel Bring Experience To TNF-Inhibitor Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Arthritis Advisory Committee will discuss Sandoz’s 351(k) application referencing Amgen's etanercept July 13.

Advertisement

Related Content

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
Biosimilars: Does FDA Caution Make Advisory Committee A Rubber Stamp?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register